A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, Eduardo, Litvan, Irene, Höglinger, Günter U., Burn, David, Lees, Andrew, Andrés, María V., Gómez‐Carrillo, Belén, León, Teresa, del Ser, Teodoro, for the TAUROS Investigators·2014·Movement Disorders

DOI 10.1002/mds.25824

Cited by (326)

Items 101–200 of 326

Synthesis of Diverse 11 C-Labeled PET Radiotracers via Direct Incorporation of [ 11 C]CO 2
Andrew V. Mossine, Allen Frederick Brooks, Isaac M. Jackson, Carole Quesada, Phillip S. Sherman, Erin L. Cole, David J. Donnelly, Peter J. H. Scott, Xia Shao · 2016 · Bioconjugate Chemistry
A Review of Treatment Options for Progressive Supranuclear Palsy
María Stamelou, Günter U. Höglinger · 2016 · CNS Drugs
Drug repurposing towards targeting cancer stem cells in pediatric brain tumors
Hisham F. Bahmad, Mohamad K. Elajami, Talal El Zarif, Jolie Bou-Gharios, Thamara J. Abouantoun, Wassim G. Abou-Kheir · 2020 · Cancer and Metastasis Reviews
Further understanding of tau phosphorylation: implications for therapy
Medina, Miguel, Avila, Jesús · 2015 · Expert Review of Neurotherapeutics
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials
Duncan Street, Edwin Jabbari, Alyssa A. Costantini, Peter Simon Jones, Negin Holland, Timothy Rittman, Marte Theilmann Jensen, Viorica Chelban, Yee Yen Goh, Tong Guo et al. · 2023 · Brain
Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
María Stamelou, Jakob Schöpe, Stefan Wagenpfeil, Teodoro del Ser, Jee Bang, Iryna V. Lobach, Phi Luong, Gesine Respondek, Wolfgang Hermann Oertel, A M Boxer et al. · 2016 · Movement Disorders
Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3
Mahboubeh S. Noori, Pooja M. Bhatt, Maria Cecilia Courreges, Davoud Ghazanfari, Chaz M. Cuckler, Crina M. Orac, Mark C. McMills, Frank Schwartz, Sudhir P. Deosarkar, Stephen C. Bergmeier et al. · 2019 · American Journal of Physiology-Cell Physiology
Invited review: Drug development for tauopathies
Fiona Grüninger · 2014 · Neuropathology and Applied Neurobiology
Progressive supranuclear palsy
Nikolaos Giagkou, Günter U. Höglinger, María Stamelou · 2019 · International review of neurobiology
GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel
Abeer Alaohali, Christoph Salzlechner, Lucia K. Zaugg, Fernanda R. Suzano, Ana Martı́nez, Eileen Gentleman, Paul Thomas Sharpe · 2021 · Journal of Dental Research
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Sophia Hu, Masumi Ueda, Lindsay C. Stetson, James John Ignatz-Hoover, Stephen A. Moreton, Amit Chakrabarti, Zhiqiang Xia, Goutam Karan, Marcos J. G. De Lima, Mukesh Agrawal et al. · 2016 · Molecular Cancer Therapeutics
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
David G. Coughlin, David John Irwin · 2017 · Current Neurology and Neuroscience Reports
Cotinine improves visual recognition memory and decreases cortical Tau phosphorylation in the Tg6799 mice
J. Alex Grizzell, Sagar P. Patel, George Emilio Barreto, Valentina Echeverrı́a · 2017 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus
Tobías Engel, Raquel Gómez‐Sintes, Mariana Alves, Eva Maria Jimenez-Mateos, Marta Fernández‐Nogales, Amaya Sanz‐Rodriguez, James Morgan, Edward H. Beamer, Alberto Rodríguez-Matellán, Mark Dunleavy et al. · 2018 · Cell Death and Disease
Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Stéphane Thibault, Wenyue Hu, Brad P. Hirakawa, Dalia Y. Kalabat, Tania Franks, Tae Sung, Su Khoh‐Reiter, Shuyan Lu, Martin B. Finkelstein, Bart A. Jessen et al. · 2018 · Molecular Cancer Therapeutics
Frontrunner in Translation: Progressive Supranuclear Palsy
Ali Shoeibi, Nahid Olfati, Irene Litvan · 2019 · Frontiers in Neurology
Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
Duncan Street, Maura Malpetti, Timothy Rittman, Boyd C. P. Ghosh, Alexander G. Murley, Ian T S Coyle-Gilchrist, Luca Passamonti, James Benedict Rowe · 2021 · Brain Communications
GSK-3: a multifaceted player in acute leukemias
Alberto Maria Martelli, Camilla Evangelisti, Francesca Paganelli, Francesca Chiarini, James Andrew McCubrey · 2021 · Leukemia
The Role of Tau beyond Alzheimer’s Disease: A Narrative Review
Eleonora Virgilio, Fabiola De Marchi, Elena Contaldi, Umberto Dianzani, Roberto M. Cantello, Letizia Mazzini, Cristoforo Comi · 2022 · Biomedicines
Falls in Progressive Supranuclear Palsy
Fraser Steven Brown, James Benedict Rowe, Luca Passamonti, Timothy Rittman · 2019 · Movement Disorders Clinical Practice
A Modified Progressive Supranuclear Palsy Rating Scale
Marie‐Therese Grötsch, Gesine Respondek, Carlo Colosimo, Yaroslau Compta, Jean‐Christophe Corvol, Joaquim José Ferreira, Meret Koroni Huber, Martin Klietz, Lea Krey, Johannes Levin et al. · 2021 · Movement Disorders
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy
Georg Nübling, Mira Hensler, Sabine Paul, Andreas Zwergal, Alexander Crispin, Stefan Lorenzl · 2016 · Journal of Neurology
Partial Inhibition of Mitochondrial Complex I Reduces Tau Pathology and Improves Energy Homeostasis and Synaptic Function in 3xTg-AD Mice
Andrea Stojakovic, Su-Youne Chang, Jarred J. Nesbitt, Nicholas P. Pichurin, Mark Ostroot, Tomonori Aikawa, Takahisa Kanekiyo, Eugenia V. Trushina · 2020 · Journal of Alzheimer s Disease
Glycogen synthase kinase-3β inhibition enhances myelination in preterm newborns with intraventricular hemorrhage, but not recombinant Wnt3A
Preeti Dohare, Bokun Cheng, Ehsan Ahmed, Vivek Yadala, Pranav Singla, Sunisha Chinnu Thomas, Robert J. Kayton, Zoltan I. Ungvari, Praveen Ballabh · 2018 · Neurobiology of Disease
Therapeutic trial design for frontotemporal dementia and related disorders
P. Desmarais, J. Rohrer, Q. Nguyen, N. Herrmann, D. Stuss, A. Lang, A. Boxer, B. Dickerson, H. Rosen, J. V. van Swieten et al. · 2018 · Journal of Neurology Neurosurgery & Psychiatry
Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability
Ali Shoeibi, Irene Litvan, EDUARDO S. TOLOSA, Teodoro del Ser, Euyhyun Lee · 2019 · Parkinsonism & Related Disorders
Preclinical murine platform to evaluate therapeutic countermeasures against radiation-induced gastrointestinal syndrome
Paul Bernard Romesser, Amanda S. Kim, Jeho Jeong, Allison Mayle, Lukas E. Dow, Scott W. Lowe · 2019 · Proceedings of the National Academy of Sciences
Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β
Hisham F. Bahmad, Reda Chalhoub, Hayat Harati, Jolie Bou-Gharios, Sahar Assi, Farah Ballout, Alissar Monzer, Hiba Msheik, Tarek Araji, Mohamad K. Elajami et al. · 2020 · Pharmacological Reports
Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers
Edwin Jabbari, Henrik Zetterberg, Huw R. Morris · 2017 · Journal of Neurology Neurosurgery & Psychiatry
Available and future treatments for atypical parkinsonism. A systematic review
Davide Vito Moretti · 2018 · CNS Neuroscience & Therapeutics
New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases
Chengfeng Wang, Yu Cui, Tong Xu, Yu Zhou, Ting Wang, Ting Wang · 2023 · Biochemical Pharmacology
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Beatrice Balboni, Mirco Masi, Walter Rocchia, Stefania Girotto, Andrea Cavalli · 2023 · International Journal of Molecular Sciences
Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles
Xike Qin, Yunling Wang, Hemant K. Paudel · 2017 · American Journal Of Pathology
GSK-3 Inhibitors: A Double-Edged Sword? – An Update on Tideglusib
Theodore Lemuel Mathuram, Lisa M. Reece, Kotturathu Maman Cherian · 2018 · Drug Research
The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model
Jugajyoti Baruah, Ryan T. Hitzman, Jane Zhang, Suhnrita Chaudhuri, Victoria Mastej, Kishore K. Wary · 2017 · Journal of Biological Chemistry
The diagnosis of progressive supranuclear palsy: current opinions and challenges
Farwa Ali, Keith A. Josephs · 2018 · Expert Review of Neurotherapeutics
Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
Giancarlo Logroscino, Bruno Pietro Imbimbo, Madia Lozupone, Rodolfo Sardone, Rosa Capozzo, Petronilla Battista, Chiara Zecca, Vittorio Dibello, Gianluigi Giannelli, Antonello Bellomo et al. · 2019 · Expert Opinion on Pharmacotherapy
Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
Joaquim José Ferreira, Claudia Trenkwalder, Tiago Mestre · 2018 · Movement Disorders
Key emerging issues in progressive supranuclear palsy and corticobasal degeneration
Keith A. Josephs · 2015 · Journal of Neurology
Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo
Andrea Gramatica, Roland Schwarzer, William Brantley, Benjamin D. Varco-Merth, Hannah S. Sperber, Philip Ansumana Hull, Mauricio Montaño, Stephen A. Migueles, Danielle Nettere, Louise E. Hogan et al. · 2021 · Journal of Virology
Injectable methacrylated gelatin/thiolated pectin hydrogels carrying melatonin/tideglusib-loaded core/shell PMMA/silk fibroin electrospun fibers for vital pulp regeneration
Deniz Atila, Dilek Sendil Keskin, Yuan‐Ling Lee, Feng‐Huei Lin, Vasıf Hasırcı, Ayşen Tezcaner · 2022 · Colloids and Surfaces B Biointerfaces
Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research
Biswamohan Mishra, Pachipala Sudheer, Roopa Rajan, Ayush Agarwal, M.V. Padma Srivastava, Nilima Nilima, Venugopalan Y. Vishnu · 2024 · Heliyon
Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inductors of Structural Neuronal Plasticity
Laura Llorach-Parés, Ened Rodríguez-Urgellés, Alfons Nonell‐Canals, Jordi Alberch, Conxita Àvila, Melchor Sánchez-Martínez, Albert Giralt · 2020 · Biomolecules
The Role of Rehabilitation in Patients With Progressive Supranuclear Palsy: A Narrative Review
Domenico Intiso, Michelangelo Bartolo, Andrea Santamato, Filomena Di Rienzo · 2018 · PM&R
Preservation of neurocognitive function in the treatment of brain metastases
Michael W. Parsons, Katherine B. Peters, Scott Floyd, Paul D. Brown, Jeffrey Scott Wefel · 2021 · Neuro-Oncology Advances
Interventional trials in atypical parkinsonism
Sabine Eschlböck, Florian Krismer, Gregor Karl Wenning · 2015 · Parkinsonism & Related Disorders
Discovery of new GSK-3β inhibitors through structure-based virtual screening
Xiaodong Dou, Lan Jiang, Yanxing Wang, Hongwei Jin, Zhenming Liu, Liangren Zhang · 2017 · Bioorganic & Medicinal Chemistry Letters
Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy
Ali Shoeibi, Nahid Olfati, Irene Litvan · 2018 · Expert Opinion on Investigational Drugs
Recognizing and treating atypical Parkinson disorders
Melissa J. Armstrong, Nikolaus R. McFarland · 2019 · Handbook of clinical neurology
Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale
Sarah Hewer, Sue Varley, Adam L. Boxer, Eldho Mathew Paul, David R. Williams, on behalf of the AL‐108‐231 Investigators · 2016 · Movement Disorders
GSK-3-associated signaling is crucial to virus infection of cells
Mohammad A. Alfhili, Jawaher Alsughayyir, James Andrew McCubrey, Shaw M. Akula · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Tideglusib enhances odontogenic differentiation in human dental pulp stem cellsin vitro
Chatvadee Kornsuthisopon, Kevin A. Tompkins, Thanaphum Osathanon · 2022 · International Endodontic Journal
Development of tau phosphorylation-targeting therapies for the treatment of neurodegenerative diseases
Jingfen Su, Yue Xiao, Xiaochuan Wang, Jie Zheng, Jian‐Zhi Wang · 2024 · Medicine Plus
Update on muscle disease
Jonathan Witherick, Stefen Brady · 2018 · Journal of Neurology
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia
Peng Zhang, Zhihui Min, Yang Gao, Jiang Bian, Xin Lin, Jie He, Deyong Ye, Yilin Li, Chao Peng, Yunfeng Cheng et al. · 2021 · Journal of Medicinal Chemistry
Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies
Abdullahi Opeyemi Alausa, Sunday Ogundepo, Barakat Olaleke, Rofiat Oluwabusola Adeyemi, Mercy Olatinwo, Aminat Ismail · 2021 · Chinese Medicine
Disease-modifying therapies for tauopathies: agents in the pipeline
Francesco Panza, Bruno Pietro Imbimbo, Madia Lozupone, Antonio Greco, Davide Seripa, Giancarlo Logroscino, Antonio Daniele, Carlo Colosimo · 2019 · Expert Review of Neurotherapeutics
Therapeutic advances in multiple system atrophy and progressive supranuclear palsy
Werner H Poewe, Philipp Mahlknecht, Florian Krismer · 2015 · Movement Disorders
Small Molecule GSK-3 Inhibitors Safely Promote the Proliferation and Viability of Human Dental Pulp Stem Cells—In Vitro
Samer Hanna, Riham Mohammed Aly, Ghada Nour Eldeen, Alberto Adanero Velasco, Ruth Pérez Alfayate · 2023 · Biomedicines
Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes
Adam L. Boxer, Richard M. Tsai · 2014 · Seminars in Neurology
Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein
Rikke Hahn Kofoed, Cristine Betzer, Nelson Ferreira, Poul Henning Jensen · 2019 · Neurobiology of Disease
Drug Repurposing in Dentistry: Towards Application of Small Molecules in Dentin Repair
Anahid A. Birjandi, Fernanda R. Suzano, Paul Thomas Sharpe · 2020 · International Journal of Molecular Sciences
A modified glass ionomer cement to mediate dentine repair
Abeer Alaohali, Delia S. Brauer, Eileen Gentleman, Paul Thomas Sharpe · 2021 · Dental Materials
Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives
Dominika Przewodowska, Weronika Zofia Marzec, Natalia Madetko‐Alster · 2021 · Frontiers in Molecular Neuroscience
Dementia Therapy Targeting Tau
Luc Buée · 2019 · Advances in experimental medicine and biology
DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy
Gesine Respondek, Günter U. Höglinger · 2021 · Frontiers in Neurology
A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β
Zachary Swinney, Brad A. Haubrich, Shuangluo Xia, Chakk S. Ramesha, Stephen Raymond Gomez, Paul J. Guyett, Kojo Mensa‐Wilmot, David C. Swinney · 2016 · PLoS neglected tropical diseases
Atypical parkinsonism – new advances
María Stamelou, Kailash P. Bhatia · 2016 · Current Opinion in Neurology
The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells
Jolie Bou-Gharios, Sahar Assi, Hisham F. Bahmad, Hussein Kharroubi, Tarek Araji, Reda Chalhoub, Farah Ballout, Hayat Harati, Youssef Fares, Wassim G. Abou-Kheir · 2020 · Pharmacological Reports
Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury
Christine U. Vohwinkel, Yasmin Buchäckert, Hamza M. Al-tamari, Luciana C. Mazzocchi, Holger K. Eltzschig, Konstantin Mayer, Rory Edward Morty, Susanne Herold, Werner Seeger, Soni Savai Pullamsetti et al. · 2017 · American Journal of Respiratory Cell and Molecular Biology
Unleashing β-catenin with a new anti-Alzheimer drug for bone tissue regeneration
Marianne Comeau‐Gauthier, Magdalena Tarchala, José L. Ramírez-GarcíaLuna, Edward Joseph Harvey, Geraldine E. Merle · 2020 · Injury
Allosteric Modulation of GSK-3β as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related
Anabel Rico, Garazi Guembelzu, Valle Palomo, Ana Martı́nez, Ana Aiastui, Leire Casas-Fraile, Andrea Valls, Adolfo López de Munaín, Amets Sáenz · 2021 · International Journal of Molecular Sciences
Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy
Filomena Abate, Michela Russo, Carlo Ricciardi, Maria Francesca Tepedino, Maria Romano, Roberto Erro, Maria Teresa Pellecchia, Marianna Amboni, Paolo Barone, Marina Picillo · 2023 · Parkinsonism & Related Disorders
Identification of AS1842856 as a novel small‐molecule GSK3α/β inhibitor against Tauopathy by accelerating GSK3α/β exocytosis
Da‐Long He, Xiao‐Yu Zhang, Jing‐Yang Su, Qi Zhang, Lingxiao Zhao, Ting‐Yao Wu, Ren Hang, Rong‐Jun Jia, Xian‐Fang Lei, Wen‐Jia Hou et al. · 2024 · Aging Cell
Iron(ing) out parkinsonisms: The interplay of proteinopathy and ferroptosis in Parkinson's disease and tau-related parkinsonisms
Maria João da Costa Caiado, Amalia M. Dolga, Wilfred F.A. den Dunnen · 2024 · Redox Biology
Interventions in progressive supranuclear palsy
Christos Koros, María Stamelou · 2015 · Parkinsonism & Related Disorders
Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies
Yaqing Li, Meng‐Shan Tan, Jin‐Tai Yu, Lan Tan · 2015 · Molecular Neurobiology
Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies
Stefano Gazzina, Marta Antonia Manes, Alessandro Padovani, Barbara Borroni · 2017 · European Journal of Pharmacology
A human Tau expressing zebrafish model of progressive supranuclear palsy identifies Brd4 as a regulator of microglial synaptic elimination
Qing Bai, Enhua Shao, Denglei Ma, Binxuan Jiao, Seth D. Scheetz, Karen A. Hartnett, В. Н. Ильин, Elias Aizenman, Julia Kofler, Edward A. Burton · 2024 · Nature Communications
Meridianins Rescue Cognitive Deficits, Spine Density and Neuroinflammation in the 5xFAD Model of Alzheimer’s Disease
Ened Rodríguez-Urgellés, Anna Sancho‐Balsells, Wanqi Chen, Laura López-Molina, Iván Ballasch, Ignacio del Castillo, Conxita Àvila, Jordi Alberch, Albert Giralt · 2022 · Frontiers in Pharmacology
One decade ago, one decade ahead in progressive supranuclear palsy
María Stamelou, Nikolaos Giagkou, Günter U. Höglinger · 2019 · Movement Disorders
Single-nucleus chromatin accessibility profiling highlights distinct astrocyte signatures in progressive supranuclear palsy and corticobasal degeneration
Nils Briel, Viktoria Ruf, Katrin Pratsch, Sigrun Roeber, Jeannine Widmann, Janina Mielke, Mario M. Dorostkar, Otto Windl, Thomas Arzberger, Jochen Wolfgang Herms et al. · 2022 · Acta Neuropathologica
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations
Claire Frances Brittain, Andrew P. McCarthy, Michael C. Irizarry, Dana McDermott, Kevin Biglan, Günter U. Höglinger, Stefan Lorenzl, Teodoro del Ser, Adam L. Boxer, David R. Williams et al. · 2018 · Parkinsonism & Related Disorders
Emerging trends of injectable hydrogels for vital pulp therapy: A comprehensive review
Md Refat Readul Islam, Rafiqul Islam, Hidehiko Sano, Yu Toida, Shuhei Hoshika, Hany Mohamed Aly Ahmed, Atsushi Tomokiyo · 2025 · International Endodontic Journal
Disease-modifying strategies in primary tauopathies
Thomas W. Rösler, Márcia Costa, Günter U. Höglinger · 2019 · Neuropharmacology
Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer’s pathologies?
Sushmitaa Dhevii Manoharan, Hafizah Abdul Hamid, Nur Fariesha Md Hashim, Manraj Singh Cheema, Samaila Musa Chiroma, Muzaimi Mustapha, Muhammad Zulfadli Mehat · 2024 · Brain Research
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review
Elise E. Dunning, Boris Decourt, Nasser H. Zawia, Holly A. Shill, Marwan Noel Sabbagh · 2024 · Neurology and Therapy
Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials
Cassandra Marotta, Benjamin Sinclair, Terence John O'Brien, Lucy E. Vivash · 2024 · Brain Communications
Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Marcello Giunta, Eino Solje, Fabrizio Gardoni, Barbara Borroni, Alberto Benussi · 2021 · Journal of Experimental Pharmacology
Therapeutic strategies for tauopathies and drug repurposing as a potential approach
Majedul Islam, Fengyun Shen, Deepika Regmi, Deguo Du · 2022 · Biochemical Pharmacology
Sample size calculations for clinical trials targeting tauopathies: a new potential disease target
Jennifer Louise Whitwell, Joseph R. Duffy, Edythe A. Strand, Mary M. Machulda, Nirubol Tosakulwong, Stephen D. Weigand, Matthew L. Senjem, Anthony J. Spychalla, Jeffrey L. Gunter, Ronald Carl Petersen et al. · 2015 · Journal of Neurology
The tau of PSP: A long road to treatment
Lawrence I. Golbe · 2014 · Movement Disorders
FTLD Treatment: Current Practice and Future Possibilities
Peter Alexander Ljubenkov, Adam L. Boxer · 2021 · Advances in experimental medicine and biology
Freezing of gait is an early clinical feature of progressive supranuclear palsy
Yasushi Osaki, Yukari Morita, Yuka Miyamoto, Kounosuke Furuta, Hirokazu Furuya · 2017 · Neurology and Clinical Neuroscience
Ethnic Differences in Atypical Parkinsonism—is South Asian PSP Different?
Bettina Balint, Shermyn Neo, Francesca Magrinelli, Eoin Mulroy, Anna Latorre, María Stamelou, Huw R. Morris, Amit Batla, Kailash P. Bhatia · 2024 · Movement Disorders Clinical Practice
Odontogenic differentiation of dental pulp stem cells by glycogen synthase kinase-3β inhibitory peptides
Vidhyashree Rajasekar, Mohamed Mahmoud Abdalla, Mohammed S. Basbrain, Prasanna Neelakantan, Cynthia Kar Yung Yiu · 2025 · Stem Cell Research & Therapy
Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
Masumi Ueda, Tammy Stefan, Lindsay C. Stetson, James John Ignatz-Hoover, Benjamin Kent Tomlinson, Richard J. Creger, Brenda Cooper, Hillard Michael Lazarus, Marcos J. G. De Lima, David N. Wald et al. · 2020 · Frontiers in Oncology
Tau Diagnostics and Clinical Studies
Illana Gozes, Günter U. Höglinger, James P. Quinn, Nigel M. Hooper, Kina Höglund · 2017 · Journal of Molecular Neuroscience
Progress in the treatment of Parkinson-Plus syndromes
Nahid Olfati, Ali Shoeibi, Irene Litvan · 2018 · Parkinsonism & Related Disorders
The gut-brain axis in the pathogenesis of Parkinson’s disease
Lanxia Meng, Xin Yuan, Xuebing Cao, Zhentao Zhang · 2019 · Brain Science Advances